Supplemental experimental procedures Quantitative real-time PCR (qRT-PCR) analyses
The qRT-PCR analysis was performed as previously described 1 . Briefly, CGNs were treated with baclofen or with the vehicle for indicated times, then lysed using TRIzol reagent (Invitrogen). Total RNA was prepared according to the manufacturer's instructions. The RNA concentration was determined and PCR analysis was performed using the following sense and antisense primers: fmr1, 5′-CCG AAC AGA TAA TCG TCC ACG-3′, antisense,
5′-ACG CTG TCT GGC TTT TCC TTC-3′ and glyceraldehyde-3-phosphate
dehydrogenase, 5′-TCG GAG TCA ACG GAT TTG GTC GT-3′ and 5′-TGCCATGGGTGGAATCATATTGGA-3′ (used as a reference gene).
RNA interference experiments
Mammalian shRNA constructs were designed as previously described 3 plasmids 24 h later before drug treatment.
Drug treatments
Cultures were washed once with HBS (HEPES-buffered solution, 10 mM HEPES, 140 mM NaCl, 4 mM KCl, 2 mM MgSO 4 , 1 mM KH 2 PO 4 , Ca 2+ free, pH 7.4) and pre-incubated at 37°C with HBS for 60 min. Cells were treated by adding freshly made drugs to HBS.
Inhibitors were pretreated in cells as followed: CGP54626 (10 M, 20min), Gö-6983 (2 μM, CGNs were pretreated with Gö-6983, followed by treatment with baclofen. Akt, ERK 1/2 , and CREB phosphorylation levels were quantified by western blotting, and the protein ratio was defined as the ratio between the density of each band and the sum of the densities of all the bands in a given blot. Data represent the mean ± SEM from three independent experiments. ***P < 0.001 vs. basal level. ### P < 0.001; ns, not significant vs. baclofen treated group. (B)
MEFs co-transfected with GABA B1 and GABA B2 were pretreated with control or PKCβII siRNA, followed by treatment with baclofen. PKCβII, pERK 1/2 , and pCREB levels were analyzed by western blotting. 
